Lifecore (LFCR) Biomedical announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full payment ahead of schedule, opting to deliver the remaining balance as a lump sum rather than over the originally agreed 18-month installment plan. Lifecore had previously received $7 million at the close of the $17 million transaction in early 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore names Mark DaFonseca as Chief Commercial Officer
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Lifecore initiated with an Outperform at William Blair
- Lifecore Biomedical’s Promising Growth Trajectory: Buy Rating with 34% Upside Potential
- Lifecore appoints Salus as chief legal, administration officer